Research programme: histamine H3 receptor antagonists - Arena Pharmaceuticals

Drug Profile

Research programme: histamine H3 receptor antagonists - Arena Pharmaceuticals

Latest Information Update: 21 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Hypersomnia; Sleep disorders

Most Recent Events

  • 21 Aug 2008 Preclinical pharmacokinetics data presented at the 236th American Chemical Society National Meeting (236th-ACS-2008) ,,
  • 05 Sep 2007 Preclinical trials in Hypersomnia in USA (unspecified route)
  • 05 Sep 2007 Preclinical trials in Sleep disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top